← Back to Clinical Trials
Recruiting NCT05598983

NCT05598983 Non-contact Proactive Remote Monitoring of COPD Exacerbations

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05598983
Status Recruiting
Phase
Sponsor Life Detection Technologies
Condition COPD Exacerbation
Study Type OBSERVATIONAL
Enrollment 75 participants
Start Date 2023-05-15
Primary Completion 2026-05-15

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 75 participants in total. It began in 2023-05-15 with a primary completion date of 2026-05-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this observational study is to determine if a COPD exacerbation can be detected early in its onset. The main questions it aims to answer are: * Can an exacerbation be detected before the person recognizes they are unwell? * What are the biological signals which provide the best indication of decompensation? * How does this indication of decompensation compare to a daily CAT? Participants will be asked to place a device, DistaSense, on top of their mattress and then sleep as normal. In addition, they will be asked to complete a daily CAT.

Eligibility Criteria

Inclusion Criteria: 1. Confirmed diagnosis of COPD 2. 1 or more exacerbation in the last year 3. Aged over 18 years 4. Willing to use monitoring devices and complete study questionnaires 5. Adequate English 6. Signed consent form Exclusion Criteria: 1. Pregnancy 2. BMI greater than 45 kg/m2 3. Nil other, provided inclusion criteria are met.

Contact & Investigator

Central Contact

Eric Howie

✉ ehowie@distasense.com

📞 4084213151

Principal Investigator

John Hurst

PRINCIPAL INVESTIGATOR

University College, London

Frequently Asked Questions

Who can join the NCT05598983 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying COPD Exacerbation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05598983 currently recruiting?

Yes, NCT05598983 is actively recruiting participants. Contact the research team at ehowie@distasense.com for enrollment information.

Where is the NCT05598983 trial being conducted?

This trial is being conducted at London, United Kingdom.

Who is sponsoring the NCT05598983 clinical trial?

NCT05598983 is sponsored by Life Detection Technologies. The principal investigator is John Hurst at University College, London. The trial plans to enroll 75 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology